Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08NMV
|
|||
| Former ID |
DNCL003697
|
|||
| Drug Name |
Ixekizumab
|
|||
| Synonyms |
LY2439821
Click to Show/Hide
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Plaque psoriasis [ICD-11: EA90.0; ICD-10: L40.0] | Approved | [1] | |
| Psoriatic arthritis [ICD-11: FA21; ICD-9: 696] | Phase 3 | [2], [3] | ||
| Company |
Eli Lilly
|
|||
| ADReCS Drug ID | BADD_D01224 | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Interleukin-17 (IL17) | Target Info | Modulator | [4], [5] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| Inflammatory bowel disease (IBD) | ||||
| Rheumatoid arthritis | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| Panther Pathway | Interleukin signaling pathway | |||
| Pathway Interaction Database | IL27-mediated signaling events | |||
| IL23-mediated signaling events | ||||
| WikiPathways | TCR Signaling Pathway | |||
| Allograft Rejection | ||||
| IL17 signaling pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76. | |||
| REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7541). | |||
| REF 3 | ClinicalTrials.gov (NCT01474512) A Phase 3 Study in Participants With Moderate to Severe Psoriasis. U.S. National Institutes of Health. | |||
| REF 4 | Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal. Br J Dermatol. 2012 Oct;167(4):710-3; discussion 714-5. | |||
| REF 5 | A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response totumor necrosis factor inhibitors. Arthritis Rheumatol. 2014 Jul;66(7):1693-704. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.